Hypertriglyceridemia (HTG) is a well-established etiology of acute pancreatitis (AP), accounting for approximately 4.7–14.3 % of all cases globally [1,2]. Recurrent acute pancreatitis (RAP) is one of the long-term complications of hypertriglyceridemia-associated acute pancreatitis (HTG-AP). RAP contributes significantly to the overall disease burden by necessitating repeated hospitalizations, negatively affecting the quality of life, and increasing the risk of developing chronic pancreatitis and pancreatic cancer [3–5].
